Show simple item record

dc.contributor.authorBlowers, Elaine
dc.contributor.authorHall, Kate
dc.date.accessioned2009-06-02T14:05:00Z
dc.date.available2009-06-02T14:05:00Z
dc.date.issued2009-02
dc.identifier.citationAdverse events in bevacizumab and chemotherapy: patient management., 18 (7):424-8 Br J Nursen
dc.identifier.issn0966-0461
dc.identifier.pmid19373187
dc.identifier.urihttp://hdl.handle.net/10541/69598
dc.description.abstractBevacizumab (Avastin) is an anti-angiogenic agent recently approved for the treatment of metastatic breast cancer in combination with paclitaxel. It is important that nurses are familiar with the side-effects associated with this agent--several of which differ from those seen with traditional chemotherapy agents--and how these can be optimally identified, monitored and managed. Side-effects associated with bevacizumab include hypertension, proteinuria, thromboembolic events, bleeding, cardiac toxicity, wound-healing complications and gastrointestinal perforations. Many of these are easily manageable, often without the need to discontinue bevacizumab therapy. This article, the second in a series, provides nurses with management recommendations for these toxicities in order to deliver optimal patient care and improve patients quality of life.
dc.language.isoenen
dc.subjectBevacizumaben
dc.subjectBreast Canceren
dc.subjectChemotherapyen
dc.subjectNurse Educationen
dc.subjectSide Effectsen
dc.titleAdverse events in bevacizumab and chemotherapy: patient management.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Foundation Trust, Manchester.en
dc.identifier.journalBritish Journal of Nursingen
html.description.abstractBevacizumab (Avastin) is an anti-angiogenic agent recently approved for the treatment of metastatic breast cancer in combination with paclitaxel. It is important that nurses are familiar with the side-effects associated with this agent--several of which differ from those seen with traditional chemotherapy agents--and how these can be optimally identified, monitored and managed. Side-effects associated with bevacizumab include hypertension, proteinuria, thromboembolic events, bleeding, cardiac toxicity, wound-healing complications and gastrointestinal perforations. Many of these are easily manageable, often without the need to discontinue bevacizumab therapy. This article, the second in a series, provides nurses with management recommendations for these toxicities in order to deliver optimal patient care and improve patients quality of life.


This item appears in the following Collection(s)

Show simple item record